Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients

Breast

Volumn 16, Issue 3, 2007, Pages 307-315

  Yu, Ke Da ^a   Liu, Guang Yu ^a   Di, Gen Hong ^a   Wu, Jiong ^a   Lu, Jin Song ^a   Shen, Kun Wei ^a   Shen, Zhen Zhou ^a   Shao, Zhi Ming ^a  

^a Cancer Hospital   (China)

Author keywords

Aged; Breast neoplasms; Endocrine therapy; Prediction; Progesterone receptors

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 34249017035     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.12.011     Document Type: Article

References (20)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group. Lancet 351 (1998) 1451-1467
4. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., and Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21 (2003) 1973-1979
5. Glass E.L., Heffelfinger S., Blau R., and Lower E.E. Estrogen receptor and progesterone receptor status: differences between primary and metastatic breast cancer. Breast Cancer Res Treat 82 (2003) S60
6. Ravdin P.M., Green S., Dorr T.M., et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10 (1992) 1284-1291
7. Honma N., Sakamoto G., Akiyama F., et al. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 42 (2003) 120-127
8. Thorpe S.M. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol 27 (1988) 1-19
9. Shimada A., Kimura S., Abe K., et al. Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections. Proc Natl Acad Sci USA 82 (1985) 4803-4807
10. Rody A., Diallo R., Poremba C., et al. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncol Rep 12 (2004) 695-699
11. Bonetti M., and Gelber R.D. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19 (2000) 2595-2609
12. Jacobsen B.M., Schittone S.A., Richer J.K., and Horwitz K.B. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19 (2005) 574-587
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
14. MacGrogan G., Soubeyran I., DeMascarel I., et al. Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas-a correlative study of 942 cases. Appl Immunohistochem 4 (1996) 219-227
15. Bernoux A., de Cremoux P., Laine-Bidron C., et al. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Breast Cancer Res Treat 49 (1998) 219-225
16. Cui X.J., Schiff R., Arpino G., Osborne C.K., and Lee A.V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23 (2005) 7721-7735
17. Dowsett M. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 82 (2003) S7
18. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
19. Kim H.J., Cui X., Hilsenbeck S.G., and Lee A.V. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 12 (2006) 1013s-1018s
20. Gago F.E., Fanelli M.A., and Ciocca D.R. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mol Biol 98 (2006) 36-40